Avadel Pharmaceuticals PLC 8-K filings

Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, integrating LUMRYZ and a commercial team to accelerate its entry into the sleep medicine market.

The High Court of Ireland has scheduled a hearing for February 10, 2026, to sanction the proposed acquisition of Avadel Pharmaceuticals by Alkermes plc.

Avadel Pharmaceuticals plc shareholders overwhelmingly approved the proposed acquisition by Alkermes plc at special meetings held on January 12, 2026.

Avadel Pharmaceuticals announced the completion of patient enrollment in its Phase 3 REVITALYZ trial for LUMRYZ in idiopathic hypersomnia, with data expected in Q2 2026.

The waiting period under the Hart-Scott-Rodino Act has expired for Alkermes' acquisition of Avadel Pharmaceuticals, satisfying a key closing condition.

Alkermes plc has increased its offer to acquire Avadel Pharmaceuticals plc to up to $22.50 per share, including a superior contingent value right, following a competing proposal.

Avadel Pharmaceuticals' Board of Directors has determined that an unsolicited acquisition proposal from H. Lundbeck A/S, valuing the company at up to $2.4 billion, constitutes a 'Company Superior Proposal' over its existing agreement with Alkermes plc.

Avadel Pharmaceuticals' board deems an unsolicited $23.00 per share offer from Lundbeck potentially superior to its existing $20.00 per share deal with Alkermes.

Avadel Pharmaceuticals reported robust third-quarter 2025 financial results, driven by strong LUMRYZ revenue growth, alongside a pending acquisition by Alkermes plc and a global settlement with Jazz Pharmaceuticals.

Alkermes plc announced a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $20.00 per share in cash and contingent value rights, valuing Avadel at approximately $2.1 billion.

Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement resolving all litigation and establishing a long-term licensing agreement for LUMRYZ.

Avadel Pharmaceuticals' subsidiary, Avadel CNS, has been ordered by a U.S. District Court to pay Jazz Pharmaceuticals an ongoing 3.85% royalty on LUMRYZ sales until February 2036 due to patent infringement.

Avadel Pharmaceuticals secures exclusive global rights to valiloxybate, a novel once-at-bedtime oxybate for sleep disorders, through a licensing agreement with XWPharma Ltd.

Avadel Pharmaceuticals reported strong Q2 2025 financial results, including a 64% increase in LUMRYZ net revenue and positive net income, leading to an upward revision of its full-year 2025 revenue guidance.

Avadel Pharmaceuticals plc announced that its shareholders re-elected all seven director nominees and ratified Deloitte & Touche LLP as its independent auditor for the 2025 fiscal year at the recent Annual Meeting.

Avadel Pharmaceuticals PLC announced that the D.C. Court of Appeals unanimously affirmed the FDA's approval of its narcolepsy drug, LUMRYZ, dismissing a challenge from Jazz Pharmaceuticals.

Avadel Pharmaceuticals announced that its drug LUMRYZ has received Orphan Drug Designation from the FDA for the treatment of idiopathic hypersomnia, potentially offering significant benefits for patients with this rare sleep disorder.

Avadel Pharmaceuticals has appointed Susan Rodriguez as its Chief Operating Officer to lead commercial strategy and operations, including the launch and expansion of LUMRYZ.

Avadel Pharmaceuticals announces a 93% increase in LUMRYZ net revenue for Q1 2025 and raises its full-year guidance, driven by strong patient demand and a favorable court ruling.

Avadel Pharmaceuticals secures a favorable ruling in its appeal against a Delaware court injunction, allowing the company to pursue FDA approval and further development of LUMRYZ for indications beyond narcolepsy.

Avadel Pharmaceuticals reported improved patient demand metrics for LUMRYZ in Q1 2025 and addressed potential tariff impacts at the Needham Virtual Healthcare Conference.

Avadel Pharmaceuticals' Compensation Committee approved equity grants, including stock options and restricted share awards, for its CEO, CFO, and General Counsel, contingent on performance-based vesting schedules.

Avadel Pharmaceuticals announces positive Q4 2024 and full-year results, driven by a 158% year-over-year increase in LUMRYZ sales, and reiterates its 2025 financial guidance.

Avadel Pharmaceuticals reports a significant increase in LUMRYZ revenue for 2024 and outlines plans for further growth in 2025, including a 50% revenue increase target.

Avadel Pharmaceuticals announces the resignation of its Chief Commercial Officer, Richard Kim, effective December 31, 2024.

Avadel Pharmaceuticals announced a successful third quarter of 2024, highlighted by $50 million in net revenue from LUMRYZ sales and FDA approval for pediatric use.

Avadel Pharmaceuticals secures a favorable court ruling, upholding the FDA's approval of LUMRYZ, a once-at-bedtime treatment for narcolepsy.

Avadel Pharmaceuticals announced FDA approval for LUMRYZ to treat cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients aged 7 and older, along with Orphan Drug Exclusivity until 2031.

Avadel Pharmaceuticals confirms that the FDA review of its sNDA for LUMRYZ in pediatric narcolepsy patients is ongoing, despite the target action date passing.

Avadel Pharmaceuticals secured a court victory allowing the commercial launch of LUMRYZ for narcolepsy, but faces a setback regarding its use for idiopathic hypersomnia.